MPR22h
FDA Decision on Etripamil Nasal Spray Delayed Due to Nonclinical Issues
The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...
Physician's Weekly1d
Comparative Effectiveness of Biologics in Severe Asthma with Nasal Polyps
The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...
Here's why school nurses need Texas law change to give new epi nasal spray to students
This is great news, but families can't just hand over the nasal spray form to their school nurse. The Texas law allowing ...
US FDA declines to approve Milestone's heart rhythm nasal spray; shares halve
Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of ...
US FDA declines to approve Milestone's heart rhythm nasal spray
Milestone Pharmaceuticals said on Friday that the U.S. health regulator had declined to approve its nasal spray to treat a ...
Milestone Pharmaceuticals Shares Hit New Low After FDA Rejects Etripamil
Milestone in 2023 agreed to sell a royalty interest in etripamil to RTW Investments for $75 million, subject to the company receiving FDA approval of the drug by the end of September 2025. Write to ...
Fierce Pharma5d
Manufacturing issues trip up Milestone's long-awaited FDA landmark
Clearing clinical and regulatory hurdles in the development of a fast-acting nasal spray for a heart condition has been a ...
FDA Issues Complete Response Letter for Etripamil for PSVT
CRL focused on CMC; no clinical issues relating to etripamil raised$69.7M in cash, cash equivalents and short-term investments as of December 31, ...